Navigation Links
Neurocrine Biosciences Reports Third Quarter 2013 Results
Date:10/29/2013

SAN DIEGO, Oct. 29, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its financial results for the quarter ended September 30, 2013. For the third quarter of 2013, the Company reported a net loss of $11.1 million, or $0.17 loss per share, compared to a net loss of $3.1 million, or $0.05 loss per share, for the same period in 2012. For the nine months ended September 30, 2013, the Company reported a net loss of $35.4 million, or $0.53 loss per share, as compared to net loss of $4.5 million, or $0.07 loss per share, for the first nine months of last year. At September 30, 2013, the Company had cash, cash equivalents, investments and receivables of $158.5 million.

"Our Kinect study of NBI-98854 provided valuable information regarding dose response and endpoint assessment that we have incorporated into our Kinect 2 study and overall development plan. The Kinect 2 study has also recently completed enrollment and we will have the top-line results from this Phase IIb study in December," said Kevin Gorman, Ph.D., President and Chief Executive Officer of Neurocrine Biosciences. "Additionally, this past quarter AbbVie initiated the second Phase III study of elagolix in endometriosis and is scheduled to have top-line data from the initial elagolix Phase III endometriosis study in 2014. Elagolix is also progressing in a Phase IIb study of uterine fibroids patients."

Revenues for the third quarter of 2013 were $0.7 million, compared to $9.4 million for the same period in 2012. Revenues for the nine months ended September 30, 2013 were $2.2 million, compared to $31.2 million for the first nine months of 2012. The entire reduction in revenue from 2012 to 2013 is due to the successful completion of the sponsored research and development phases of the Company's license agreements with both AbbVi
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Neurocrine Biosciences Reports Second Quarter 2013 Results
2. Neurocrine Biosciences Announces Conference Call And Webcast To Present Second Quarter 2013 Financial Results
3. Neurocrine Biosciences To Present At The Bank of America Merrill Lynch 2013 Health Care Conference
4. Neurocrine Biosciences Reports Fourth Quarter And Year End 2012 Results
5. Neurocrine Biosciences To Present At The 24th Annual Piper Jaffray Healthcare Conference
6. Neurocrine Biosciences Reports Third Quarter 2012 Results
7. Neurocrine Biosciences Reports Second Quarter 2012 Results
8. Neurocrine Biosciences to Present at The 24th Annual Roth Conference
9. Neurocrine Biosciences to Present at the Citi 2012 Global Health Care Conference
10. Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference
11. Proove Biosciences Will Be Exhibiting At The 2013 Common Sense Pain Management Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... light, rather than electricity, to move data would ... is a growing concern as chips, transistor counts ... optical circuits light emitters, modulators, and detectors ... promising light source for optical chips is molybdenum ... deposited as a single, atom-thick layer. Other experimental ...
(Date:9/19/2014)... 19, 2014  An entire month is dedicated to ... – Charcot-Marie-Tooth disease (CMT) – a debilitating neuromuscular disease ... muscle atrophy, weakness, and foot and hand deformities. CMT ... worldwide. CMT is a progressive disease, and over time ... mobility devices such as leg braces, wheelchairs and scooters ...
(Date:9/19/2014)... 19, 2014  Nektar Therapeutics (NASDAQ: ... characterizing the analgesic profiles of a series of ... agonist molecules. The preclinical research candidates were created ... The analgesic properties of kappa receptor ... 1,2 Kappa opioid receptors are expressed in ...
(Date:9/19/2014)... SPRINGS, Florida , September 19, 2014 ... companies release latest developments, patents and results of studies ... GNSZ), Eli Lilly and Company (NYSE: LLY ... Celgene Corporation (NASDAQ: CELG ) and Arena ... GNSZ), a leader in developing prodrug therapeutics for the ...
Breaking Biology Technology:Toward optical chips 2Toward optical chips 3September is Charcot-Marie-Tooth (CMT) Awareness Month - Scheduled events, activities and important partnerships announced throughout the month! 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 5Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 2Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 3Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 4Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 5Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 6Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 7
... SAN DIEGO, Oct. 28 Neurocrine Biosciences,(Nasdaq: NBIX ) announces the ... 2008 Financial Results, When: October 28, 2008 @ ... http://www.videonewswire.com/event.asp?id=52783 , How: Live over the Internet ... above., Contact: Claudia ...
... U.S. Phase II Study,of Nitazoxanide in Treatment-Naive Patients ... Oct. 28 Romark Laboratories, a privately,held biopharmaceutical ... at the upcoming 59th Annual Meeting of the ... also known as The,Liver Meeting(R), and the 50th ...
... Ziplex automated gene-expression system at the ... ... Molecular, a pioneer in,the development of cost-effective, easy-to-use gene-expression analysis,systems, ... L. Wittliff, a professor in the Department of,Biochemistry and Molecular ...
Cached Biology Technology:Romark Laboratories Announces Presentation of New Nitazoxanide Data at 59th Annual AASLD Meeting and 50th Anniversary IASL Meeting in San Francisco 2James L. Wittliff, Ph.D., FACB, to Present 'Predicting Breast Cancer Outcome with Gene Expression Signatures on the Ziplex(R) System' at the Association for Molecular Pathology Conference, October 30 2James L. Wittliff, Ph.D., FACB, to Present 'Predicting Breast Cancer Outcome with Gene Expression Signatures on the Ziplex(R) System' at the Association for Molecular Pathology Conference, October 30 3
(Date:9/18/2014)... in DNA, tiny strands of nucleic acid that contain ... this genetic data, our DNA is copied into RNA ... perform tasks in our cells. , Several years ... Unlike all other known RNAs, this molecule is circular, ... abundant, little has been known about how they are ...
(Date:9/18/2014)... ALEXANDRIA, Va.Sept. 18, 2014Many Americans across racial and ... the greatest impact on their day-to-day life, more ... memory, hearing and speech (57% of African-Americans, 49% ... of Hispanics). When asked which disease or ailment ... blindness ranked first among African-Americans followed by AIDS/HIV. ...
(Date:9/18/2014)... have devastated algal forests in the eastern Mediterranean Sea ... if their distribution continues to expand as the climate ... international team of researchers led by Dr Adriana Vergs ... Mediterranean Institute for Advanced Studies in Spain, is published ... the team surveyed more than 1000 kilometres of coastline ...
Breaking Biology News(10 mins):Scientists find how mysterious 'circular RNA' is formed, claim muscular dystrophy link 2Americans rate losing eyesight as having greatest impact on their lives 2Americans rate losing eyesight as having greatest impact on their lives 3Tropical fish a threat to Mediterranean Sea ecosystems 2
... of life -- kids get sick and have fevers. ... but in some small children they spark convulsions called ... very upsetting to parents," said Robert L. Macdonald, M.D., ... something of an enigma, he said. The epilepsy research ...
... development of drug-resistant HIV when patients take as few as ... only when patients take most of their pills. These differences ... "fitness" of the drug-resistant HIV, say AIDS researchers in a ... MPH, an AIDS specialist at the University of California, San ...
... Vaccine and Infectious Disease Organization (VIDO) have developed a vaccine ... against a disease for which no vaccines are yet available. ... this vaccination technique may be effective against HCV. The study ... , The team, funded by the Canadian Institutes of Health ...
Cached Biology News:Molecular mechanism may explain how fevers spark seizures 2Molecular mechanism may explain how fevers spark seizures 3Viral 'fitness' explains different resistance patterns to aids drugs 2U of S researchers develop new vaccine candidate against hepatitis C 2
... EVO96R and Freedom EVO384R are fast multi-channel ... in three different sizes, with a multi-channel ... deliver significant time saving, with true parallel ... setup of your assays with the Freedom ...
... are fast multi-channel pipetting platforms consisting of ... with a multi-channel head and a robotic ... with true parallel processing of sample plates ... with the Freedom EVOware program. ...
Prepared by multi-temperature ethanol fractionation with extensive charcoal treatment and dialysis.• Assay: ≥ 95 % (HPCE)• pH ~5.2 (10 mg/mL in 0.15 M NaCl)...
... Linkage: This CLS number is a ... match Cornings product number. If showing ... the old Sigma-Aldrich number (Z71,405-4) or ... Dim: diam. 60 mm volume ...
Biology Products: